
Opinion|Videos|July 16, 2024
Examining the use of PD-L1 and tTMB in the CASPIAN Trial
Key opinion leaders examine the PD-L1 expression and tissue tumor mutational burden (TMB) data from the CASPIAN trial, which evaluated the combination of durvalumab with platinum-etoposide for extensive-stage small cell lung cancer (ES-SCLC), weighing the potential predictive value of PD-L1 and tissue TMB in assessing progression-free survival (PFS) and objective response rate (ORR) outcomes.
Advertisement
Episodes in this series

- Please discuss the PD-L1 expression and tissue TMB data from the CASPIAN trial evaluating durvalumab + platinum-etoposide for extensive-stage small cell lung cancer(ES-SCLC). (Paz-Ares L, et al. Clin Cancer Res. 2024; 30:824-835.)
- Importance or non-importance of PD-L1 and tissue TMB in predicting PFS and ORR.
- The potential OS benefit of adding tremelimumab to durvalumab + EP in patients with a PD-L1 expression of >1%.
- [Q4W vs single dose tremelimumab]
- In your expert opinion, is there value in combining the tTMB score and PD-L1 expression level as predictive biomarkers of therapeutic response?
- How might ctDNA methylation overcome the limitations of tissue-based biomarker assessment in better classifying both transcription factor-driven and independent SCLC subtypes?
- How could further refinement of this technique facilitate the initial diagnosis of SCLC, rapid therapy initiation, and liquid-biopsy-guided surveillance throughout treatment?
- Please elaborate on how aspects of an inflamed, tumor microenvironment might foster greater therapeutic response to immune checkpoint blockade.
- Epithelial mesenchymal transition (EMT) status
- Expression of: T cell attractant chemokines CCL5 and CXCL10
- CD8A and CD8B, which suggests greater cytotoxic T cell infiltration and cytolytic activity
- Interferon-γ related T cell gene expression profile (GEP)
- Bruton’s tyrosine kinase
Advertisement
Related to this article

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.

The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.

Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.

The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
3
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
4
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
5

